‘We continue to see increasing investor interest in the business as our team generates significant demand for APIFINY as the only cancer-specific non-PSA blood test available in the world,’ said David Esposito, President and Chief Executive Officer of Armune BioScience. ‘We are grateful to the investment of the Grand Angels Venture Fund II for helping to complete the round and supporting our growth plans. ”
Armune expects to use the funding from this funding round to support the growth of its commercial operations and research and development initiatives aimed at new prostate, lung and breast cancer tests. Armune develops and commercializes the University of Michigan-licensed autoantibody technology developed under the direction of Arul Chinnaiyan, MD, PhD.
‘We are very pleased with the progress the Armune team has made in commercializing APIFINY,’ said Paul D’Amato, MBA, Managing Director of the Grand Angels Venture Fund II. ‘We believe that Armune technology has the potential to significantly improve care and reduce the cost of care in the risk assessment of prostate cancer, and we look forward to supporting the team’s growth plans. ”
Armune continues to expand its commercial operations in support of the rapid growth of the APIFINY volume Armune is raising a $25 million Series B round to fund further expansion of its marketing efforts and the development of new products for prostate, lung and breast cancer. Armune retained Mavericks Capital to support the Series B round
About the Bioscience of Armune
Inc., Armune BioScience Is a medical diagnostic company that develops and commercializes unique proprietary technology exclusively licensed by the University of Michigan for diagnostic and prognosis tests for prostate, lung and breast cancer. Armune was incorporated as a Delaware Corporation in 2008 with headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI. Visit http://www for more information. Armony Come on,
About the Great Angels
Grand Angels is one of Michigan’s most active and consistent investment organizations, and we are the longest-serving regional investment group offering robust mentoring coupled with patient capital. We do more than invest, because the goal of Grand Angels is to build world-class companies and entrepreneurial talent. Our members are only successful if the people we invest with are successful. This means developing talent We are therefore committed to using our financial, intellectual and networking resources to help our portfolio achieve more. We do this from our West Michigan base and are working actively to enhance the economic development of the region. Visit http://www for more information. Grand-Angels Organ
About Capital Mavericks
Mavericks Capital LLC and its licensed broker, Mavericks Capital Securities LLC, specialize in M&A consulting, capital raising and strategic partnerships across the healthcare sector. With a senior team with deep medical perspectives, core scientific knowledge and proprietary analytics, we are helping to build and facilitate innovative and lucrative solutions for our clients. Our areas of practice include therapeutics, devices, diagnostics, services and digital health. Visit http://www for more information. Maverickscape Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Armune%20Bioscience/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
